E

Evotec SE
XETRA:EVT

Watchlist Manager
Evotec SE
XETRA:EVT
Watchlist
Price: 8.5 EUR -15.59% Market Closed
Market Cap: 1.5B EUR
Have any thoughts about
Evotec SE?
Write Note

Evotec SE
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Evotec SE
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
E
Evotec SE
XETRA:EVT
Accounts Payable
€69.9m
CAGR 3-Years
7%
CAGR 5-Years
20%
CAGR 10-Years
30%
Gerresheimer AG
XETRA:GXI
Accounts Payable
€302.7m
CAGR 3-Years
15%
CAGR 5-Years
13%
CAGR 10-Years
12%
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Accounts Payable
€90.6m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Evotec SE
Glance View

Market Cap
1.5B EUR
Industry
Life Sciences Tools & Services

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,521 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

EVT Intrinsic Value
12.69 EUR
Undervaluation 33%
Intrinsic Value
Price
E

See Also

What is Evotec SE's Accounts Payable?
Accounts Payable
69.9m EUR

Based on the financial report for Sep 30, 2024, Evotec SE's Accounts Payable amounts to 69.9m EUR.

What is Evotec SE's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
30%

Over the last year, the Accounts Payable growth was -28%. The average annual Accounts Payable growth rates for Evotec SE have been 7% over the past three years , 20% over the past five years , and 30% over the past ten years .

Back to Top